| Japanese |
|---|
| Title | 99mTc-d,l-hexamethyl-propyleneamine oximeによる脳血流シンチグラフィの基礎的, 臨床的検討 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 松田博史*, 寺田一志*, 東壮太郎**, 隅屋寿*, 辻志郎*, 関宏恭****, 大場洋*, 藤井博之**, 池田清延**, 今井啓子*, 柴和弘***, 森厚文***, 久田欣一* |
|---|
| Authors(kana) | |
|---|
| Organization | *金沢大学医学部核医学科, **脳神経外科, ***金沢大学アイソトープ総合センター, ****富山医科薬科大学放射線科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 24 |
|---|
| Number | 9 |
|---|
| Page | 1329-1341 |
|---|
| Year/Month | 1987/9 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」新しい脳血流シンチグラフィ用剤である99mTc-d,l-hexamethyl-propyleneamine oximeの基礎的ならびに臨床的検討を行った. 本剤の放射化学的純度は標識直後で90%以上であったが経時的に劣化し, 40分後には80%前後であった. 血球および血清蛋白に高い親和性を示し, in vitroでは1分のインキュベーションで47%がそれらに結合した. 体内臓器分布では, 肝に最も高い集積を示し, 胆道系から小腸へ, および腎, 尿路系への排泄をみた. 脳への集積率は投与量の5%前後であり, その放射能および脳内分布は投与直後より10時間後まで一定であった. 主に脳血管障害を有する31人の患者に本剤による脳血流シンチグラフィを40回施行したところ, 32回(80%)に局所的放射能低下および増加部位が観察された. 一方, X線CTは15回(38%)に異常を示したにすぎなかった. なお, 本剤による副作用は全くみられなかった. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 99mTc-d,l-hexamethyl-propyleneamine oxime, Brain, Blood flow, Single photon emission computed tomography. |
|---|
| English |
|---|
| Title | Basic and Clinical Studies of Brain Perfusion Scintigraphy Using 99mTc-d,l-hexamethyl-propyleneamine Oxime |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Hiroshi MATSUDA*, Hitoshi TERADA*, Sotaro HIGASHI**, Hisashi SUMIYA*, Shiro TSUJI*, Hiroyasu SEKI****, Hiroshi OBA*, Hiroyuki FUJII**, Kiyonobu IKEDA**, Keiko IMAI*, Kazuhiro SHIBA***, Hirofumi MORI***, Kinichi HISADA* |
|---|
| Authors(kana) | |
|---|
| Organization | *Departments of Nuclear Medicine, **Neurosurgery, School of Medicine, Kanazawa University, ***Radioisotope Center, Kanazawa University, ****Department of Radiology, Toyama Medical Pharmaceutical University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 24 |
|---|
| Number | 9 |
|---|
| Page | 1329-1341 |
|---|
| Year/Month | 1987/9 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]Basic and clinical studies were performed on a new radiopharmaceutical for brain perfusion scintigraphy, 99mTc-d,l-hexamethyl-propyleneamine oxime. Its radiochemical purity was above 90% immediately after labeling. The purity gradually decreased with time. It was, for example, approximately 80% at 40 min after labeling. The agent showed high affinity to both blood cells and serum protein. The bounding rate with these blood components was 47% after only one minute incubation in vitro. Biodistribution study demonstrated the highest accumulation in liver accompanied with both hepatobiliary and urinary excretion. Average brain uptake was about 5% of injected dose and remained constant throughout the first 10 hours postinjection. The distribution pattern in the brain was also constant. Out of 40 brain perfusion studies using this agent in the patients mainly with cerebrovascular disorder, 32 studies (80%) revealed focal decreased or increased activity areas. On the contrary, X-ray CT scans showed abnormal low or high density areas only in 15 (38%) studies. No adverse reactions were observed in any subject. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 99mTc-d,l-hexamethyl-propyleneamine oxime, Brain, Blood flow, Single photon emission computed tomography. |
|---|